|
1
|
Tannock IF: Cancer: Resistance through
repopulation. Nature. 517:152–153. 2015. View Article : Google Scholar
|
|
2
|
Santarpia L, Lippman SM and El-Naggar AK:
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sriraman SK, Aryasomayajula B and
Torchilin VP: Barriers to drug delivery in solid tumors. Tissue
Barriers. 2:e295282014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,
et al: Identification and characterization of a new member of the
TNF family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pitti RM, Marsters SA, Ruppert S, Donahue
CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2
ligand, a new member of the tumor necrosis factor cytokine family.
J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, et al: Safety and antitumor activity of recombinant soluble Apo2
ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takeda K, Hayakawa Y, Smyth MJ, Kayagaki
N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H and Okumura K:
Involvement of tumor necrosis factor-related apoptosis-inducing
ligand in surveillance of tumor metastasis by liver natural killer
cells. Nat Med. 7:94–100. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kischkel FC, Lawrence DA, Chuntharapai A,
Schow P, Kim KJ and Ashkenazi A: Apo2L/TRAIL-dependent recruitment
of endogenous FADD and caspase-8 to death receptors 4 and 5.
Immunity. 12:611–620. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lemke J, von Karstedt S, Zinngrebe J and
Walczak H: Getting TRAIL back on track for cancer therapy. Cell
Death Differ. 21:1350–1364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Holland PM: Death receptor agonist
therapies for cancer, which is the right TRAIL? Cytokine Growth
Factor Rev. 25:185–193. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dyer MJ, MacFarlane M and Cohen GM:
Barriers to effective TRAIL-targeted therapy of malignancy. J Clin
Oncol. 25:4505–4506. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koschny R, Walczak H and Ganten TM: The
promise of TRAIL - potential and risks of a novel anticancer
therapy. J Mol Med Berl. 85:923–935. 2007. View Article : Google Scholar
|
|
13
|
Salvesen GS and Duckett CS: IAP proteins:
Blocking the road to death's door. Nat Rev Mol Cell Biol.
3:401–410. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fulda S: Inhibitor of apoptosis proteins
as targets for anticancer therapy. Expert Rev Anticancer Ther.
7:1255–1264. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai Q, Sun H, Peng Y, Lu J,
Nikolovska-Coleska Z, McEachern D, Liu L, Qiu S, Yang CY, Miller R,
et al: A potent and orally active antagonist (SM-406/AT-406) of
multiple inhibitor of apoptosis proteins (IAPs) in clinical
development for cancer treatment. J Med Chem. 54:2714–2726. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fulda S, Wick W, Weller M and Debatin KM:
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced
apoptosis and induce regression of malignant glioma in vivo. Nat
Med. 8:808–815. 2002.PubMed/NCBI
|
|
17
|
Fakler M, Loeder S, Vogler M, Schneider K,
Jeremias I, Debatin KM and Fulda S: Small molecule XIAP inhibitors
cooperate with TRAIL to induce apoptosis in childhood acute
leukemia cells and overcome Bcl-2-mediated resistance. Blood.
113:1710–1722. 2009. View Article : Google Scholar
|
|
18
|
Vogler M, Walczak H, Stadel D, Haas TL,
Genze F, Jovanovic M, Bhanot U, Hasel C, Möller P, Gschwend JE, et
al: Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis
and antitumor activity in preclinical models of pancreatic
carcinoma. Cancer Res. 69:2425–2434. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Irmler M, Thome M, Hahne M, Schneider P,
Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C,
et al: Inhibition of death receptor signals by cellular FLIP.
Nature. 388:190–195. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aoudjit F and Vuori K: Integrin signaling
in cancer cell survival and chemoresistance. Chemother Res Pract.
2012:2831812012.PubMed/NCBI
|
|
21
|
Safa AR and Pollok KE: Targeting the
anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel).
3. pp. 1639–1671. 2011, View Article : Google Scholar
|
|
22
|
Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs
BS, Lindner DJ and Borden EC: Downregulation of Bcl-2, FLIP or IAPs
(XIAP and survivin) by siRNAs sensitizes resistant melanoma cells
to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11:915–923.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bleumink M, Köhler R, Giaisi M, Proksch P,
Krammer PH and Li-Weber M: Rocaglamide breaks TRAIL resistance in
HTLV-1-associated adult T-cell leukemia/lymphoma by translational
suppression of c-FLIP expression. Cell Death Differ. 18:362–370.
2011. View Article : Google Scholar :
|
|
24
|
Zhu JY, Giaisi M, Köhler R, Müller WW,
Mühleisen A, Proksch P, Krammer PH and Li-Weber M: Rocaglamide
sensitizes leukemic T cells to activation-induced cell death by
differential regulation of CD95L and c-FLIP expression. Cell Death
Differ. 16:1289–1299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Giaisi M, Kohler R, Fulda S, Krammer PH
and Li-Weber M: Rocaglamide and a XIAP inhibitor cooperatively
sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas. Int J
Cancer. 131:1003–1008. 2012. View Article : Google Scholar
|
|
26
|
Gronthos S, Mankani M, Brahim J, Robey PG
and Shi S: Postnatal human dental pulp stem cells (DPSCs) in vitro
and in vivo. Proc Natl Acad Sci USA. 97:13625–13630. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang YP, Kong QH, Huang Y, Wang GL and
Chang KJ: Inhibition of c-FLIP by RNAi enhances sensitivity of the
human osteogenic sarcoma cell line U2OS to TRAIL-induced apoptosis.
Asian Pac J Cancer Prev. 16:2251–2256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ziauddin MF, Yeow WS, Maxhimer JB, Baras
A, Chua A, Reddy RM, Tsai W, Cole GW Jr, Schrump DS and Nguyen DM:
Valproic acid, an antiepileptic drug with histone deacetylase
inhibitory activity, potentiates the cytotoxic effect of
Apo2L/TRAIL on cultured thoracic cancer cells through
mitochondria-dependent caspase activation. Neoplasia. 8:446–457.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Micheau O, Shirley S and Dufour F: Death
receptors as targets in cancer. Br J Pharmacol. 169:1723–1744.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wiezorek J, Holland P and Graves J: Death
receptor agonists as a targeted therapy for cancer. Clin Cancer
Res. 16:1701–1708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Graves JD, Kordich JJ, Huang TH, Piasecki
J, Bush TL, Sullivan T, Foltz IN, Chang W, Douangpanya H, Dang T,
et al: Apo2L/TRAIL and the death receptor 5 agonist antibody AMG
655 cooperate to promote receptor clustering and antitumor
activity. Cancer Cell. 26:177–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fulda S: Safety and tolerability of TRAIL
receptor agonists in cancer treatment. Eur J Clin Pharmacol.
71:525–527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sayers TJ: Targeting the extrinsic
apoptosis signaling pathway for cancer therapy. Cancer Immunol
Immunother. 60:1173–1180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Menke C, Bin L, Thorburn J, Behbakht K,
Ford HL and Thorburn A: Distinct TRAIL resistance mechanisms can be
overcome by proteasome inhibition but not generally by synergizing
agents. Cancer Res. 71:1883–1892. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Daniel PT, Wieder T, Sturm I and
Schulze-Osthoff K: The kiss of death: Promises and failures of
death receptors and ligands in cancer therapy. Leukemia.
15:1022–1032. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schneider P, Olson D, Tardivel A, Browning
B, Lugovskoy A, Gong D, Dobles M, Hertig S, Hofmann K, Van Vlijmen
H, et al: Identification of a new murine tumor necrosis factor
receptor locus that contains two novel murine receptors for tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol
Chem. 278:5444–5454. 2003. View Article : Google Scholar
|
|
37
|
Wu GS, Burns TF, Zhan Y, Alnemri ES and
El-Deiry WS: Molecular cloning and functional analysis of the mouse
homologue of the KILLER/DR5 tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res.
59:2770–2775. 1999.PubMed/NCBI
|
|
38
|
van Dijk M, Halpin-McCormick A, Sessler T,
Samali A and Szegezdi E: Resistance to TRAIL in non-transformed
cells is due to multiple redundant pathways. Cell Death Dis.
4:e7022013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jänicke RU, Sprengart ML, Wati MR and
Porter AG: Caspase-3 is required for DNA fragmentation and
morphological changes associated with apoptosis. J Biol Chem.
273:9357–9360. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang XH, Sladek TL, Liu X, Butler BR,
Froelich CJ and Thor AD: Reconstitution of caspase 3 sensitizes
MCF-7 breast cancer cells to doxorubicin- and etoposide-induced
apoptosis. Cancer Res. 61:348–354. 2001.PubMed/NCBI
|
|
41
|
Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt
BR, Ho R, Ikegaki N and Brodeur GM: Resistance to tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
in neuroblastoma cells correlates with a loss of caspase-8
expression. Cancer Res. 61:1314–1319. 2001.PubMed/NCBI
|
|
42
|
Hopkins-Donaldson S, Ziegler A, Kurtz S,
Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U and Stahel
R: Silencing of death receptor and caspase-8 expression in small
cell lung carcinoma cell lines and tumors by DNA methylation. Cell
Death Differ. 10:356–364. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Duiker EW, Meijer A, van der Bilt ARM,
Meersma GJ, Kooi N, van der Zee AG, de Vries EG and de Jong S:
Drug-induced caspase 8 upregulation sensitises cisplatin-resistant
ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer.
104:1278–1287. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jia SH, Parodo J, Kapus A, Rotstein OD and
Marshall JC: Dynamic regulation of neutrophil survival through
tyrosine phosphorylation or dephosphorylation of caspase-8. J Biol
Chem. 283:5402–5413. 2008. View Article : Google Scholar
|
|
45
|
Jin Z, Li Y, Pitti R, Lawrence D, Pham VC,
Lill JR and Ashkenazi A: Cullin3-based polyubiquitination and
p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis
signaling. Cell. 137:721–735. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bellail AC, Olson JJ, Yang X, Chen ZJ and
Hao C: A20 ubiquitin ligase-mediated polyubiquitination of RIP1
inhibits caspase-8 cleavage and TRAIL-induced apoptosis in
glioblastoma. Cancer Discov. 2:140–155. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fulda S, Küfer MU, Meyer E, van Valen F,
Dockhorn-Dworniczak B and Debatin KM: Sensitization for death
receptor- or drug-induced apoptosis by re-expression of caspase-8
through demethylation or gene transfer. Oncogene. 20:5865–5877.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Casciano I, De Ambrosis A, Croce M, Pagnan
G, Di Vinci A, Allemanni G, Banelli B, Ponzoni M, Romani M and
Ferrini S: Expression of the caspase-8 gene in neuroblastoma cells
is regulated through an essential interferon-sensitive response
element (ISRE). Cell Death Differ. 11:131–134. 2004. View Article : Google Scholar
|
|
49
|
Fulda S and Debatin KM: IFNgamma
sensitizes for apoptosis by upregulating caspase-8 expression
through the Stat1 pathway. Oncogene. 21:2295–2308. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Crowder RN and El-Deiry WS: Caspase-8
regulation of TRAIL-mediated cell death. Exp Oncol. 34:160–164.
2012.PubMed/NCBI
|
|
51
|
Soung YH, Lee JW, Kim SY, Sung YJ, Park
WS, Nam SW, Kim SH, Lee JY, Yoo NJ and Lee SH: Caspase-8 gene is
frequently inactivated by the frameshift somatic mutation
1225_1226delTG in hepatocellular carcinomas. Oncogene. 24:141–147.
2005. View Article : Google Scholar
|
|
52
|
Shirley S and Micheau O: Targeting c-FLIP
in cancer. Cancer Lett. 332:141–150. 2013. View Article : Google Scholar
|
|
53
|
Wajant H, Haas E, Schwenzer R, Muhlenbeck
F, Kreuz S, Schubert G, Grell M, Smith C and Scheurich P:
Inhibition of death receptor-mediated gene induction by a
cycloheximide-sensitive factor occurs at the level of or upstream
of Fas-associated death domain protein (FADD). J Biol Chem.
275:24357–24366. 2000. View Article : Google Scholar : PubMed/NCBI
|
